Library — CHDR

Search

Filter

Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease.

Prins S, de Kam ML, Teunissen CE, Groeneveld GJ

Alzheimer's research & therapy, 2022 Aug; 14(1):106

View publication
A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator.

den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, Grievink HW, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen VC, Hilt DC, Groeneveld GJ

British journal of clinical pharmacology, 2021 Feb

View publication
First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M -receptor partial agonist for the treatment of dementias.

Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, van der Doef TF, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ

British journal of clinical pharmacology, 2020 Dec

View publication
Quantifying Beta-Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling.

Kanhai K, Goulooze SC, Stevens J, Hay JL, Dent G, Verma A, Hankemeier T, de Boer T, Meijering H, Chavez JC, Cohen AF, Groeneveld GJ

Clinical and translational science, 2016 Nov; 9(6):321-327

View publication
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.

Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM

British journal of clinical pharmacology, 2012 Jun; 74(1):42-53

View publication